Friday, 16 October 2026European Markets

GPE GROUP PIZZORNO Stock Bullish By 30% In The Last 21 Sessions

Loading stream...

(vianews) - shares of gpe group pizzorno (cac 40: gpe.pa) rose by a staggering 30.16% in 21 sessions from €44.1 to €57.40 at 14:53 est on monday, following the last session's upward trend. cac 40 is sliding 0.12% to €7,262.01, after two successive sessions in a row of gains.

about gpe group pizzorno

groupe pizzorno environnement provides environmental services primarily in france. it engages in the production and recycling of secondary raw materials; development of technologies and services for the recovery of bio-waste; production of heat and electricity from waste treatment; and processing and collection of household waste, as well as offers cleanliness services. groupe pizzorno environnement was founded in 1974 and is headquartered in draguignan, france.

earnings per share

as for profitability, gpe group pizzorno has a trailing twelve months eps of €5.18.

pe ratio

gpe group pizzorno has a trailing twelve months price to earnings ratio of 11.08. meaning, the purchaser of the share is investing €11.08 for every euro of annual earnings.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, gpe group pizzorno's stock is considered to be oversold (<=20).

volatility

gpe group pizzorno's last week, last month's, and last quarter's current intraday variation average was 1.28%, 1.53%, and 1.58%.

gpe group pizzorno's highest amplitude of average volatility was 2.01% (last week), 2.22% (last month), and 1.58% (last quarter).

volume

today's last reported volume for gpe group pizzorno is 490 which is 13.66% below its average volume of 461.

more news about gpe group pizzorno (gpe.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com